Triptan non-response in a London tertiary headache centre: What can we learn? A retrospective study
Cephalalgia · 2024
DOI: 10.1177/03331024241278911 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cephalalgia, 2024. Verfasst von Robyn-Jenia Wilcha und 1 weiteren Autor:innen. Beteiligte Einrichtung: NIHR King's Clinical Research Facility, SLaM Biomedical Research Centre, and Wolfson Sensory, Pain and Regeneration Centre, King's College London, Lo…. Hauptthemen laut MEDLINE: Tryptamines, Migraine Disorders, Tertiary Care Centers. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Triptans revolutionized the acute treatment of migraine; however, varied responses to triptans, as a result of poor efficacy and tolerability, are reported. A standardized definition of triptan non-response was recently proposed by the European Headache Federation (EHF). There is currently limited data available on the prevalence of triptan non-response.
Methods
We used clinic letters over a two-year duration to evaluate the triptan response and triptan efficacy or tolerability failure, or both, in a London-based tertiary headache service.
Results
In total, 419 adult migraine patients (females: 83.8%, age: 46 ± 18 years, chronic migraine: 88.5%) were included in a service evaluation. In line with the EHF definitions, “triptan non-response” was seen in 63.8% of patients (264/414), whereas 37.7% of patients (156/414) had failed at least two triptans (EHF “triptan resistant”) and 4.6% of patients (19/414) had failed at least three triptans, including a subcutaneous formulation (EHF “triptan refractory”). Notably, 21.3% of patients (88/414) had failed at least three triptans inclusive and exclusive of subcutaneous triptan use. Advancing age ( p < 0.001) and the presence of medication overuse ( p = 0.006) increased the probability of triptan response, whereas an increased number of failed preventives ( p < 0.001) and the use of calcitonin gene-related peptide monoclonal antibodies ( p = 0.022) increased the probability of triptan non-response. The largest proportion of patients responded to eletriptan (49.5%), followed by nasal zolmitriptan (44.4%) and rizatriptan (35.7%).
Conclusions
Our findings highlight an alarming prevalence of triptan non-response among adult migraineurs receiving treatment in a London-based tertiary headache service. It is imperative for clinicians to explore methods to optimize acute medication efficacy, whether this comprises changing to a triptan with a superior response rate, advocating for early intervention or considering alternative acute medication classes, such as gepants or ditans.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NIHR King's Clinical Research Facility, SLaM Biomedical Research Centre, and Wolfson Sensory, Pain and Regeneration Centre, King's College London, London, UK.
- Department of Neurology, University of California, Los Angeles, CA, USA.
ORCID-Profile: Robyn-Jenia Wilcha, Peter J Goadsby
Zitieren
APA
Wilcha, R. J., & Goadsby, P. J. (2024). Triptan non-response in a London tertiary headache centre: What can we learn? A retrospective study. Cephalalgia. https://doi.org/10.1177/03331024241278911
Vancouver
Wilcha RJ, Goadsby PJ. Triptan non-response in a London tertiary headache centre: What can we learn? A retrospective study. Cephalalgia. 2024. doi:10.1177/03331024241278911
BibTeX
@article{Wilcha2024,
author = {Wilcha, Robyn-Jenia and Goadsby, Peter J},
title = {Triptan non-response in a London tertiary headache centre: What can we learn? A retrospective study},
journal = {Cephalalgia},
year = {2024},
doi = {10.1177/03331024241278911}
}
EUVIMED